Abbott Stock Falls 7% After Q4 Earnings and 2026 Outlook Miss Expectations

Abbott Laboratories shares dropped 7% on January 22, 2026, after the company reported fourth-quarter earnings that fell short of expectations and provided a weaker-than-anticipated 2026 revenue outlook. The decline followed a fiscal 2025 full-year revenue of $53.8 billion, below analysts’ estimates of $54.2 billion, with adjusted EPS at $1.92 versus the expected $1.98. Investors reacted negatively to the guidance, which projected 2026 revenue growth of 3% to 4%, lower than the prior forecast of 5% to 6%. The underperformance was driven by softer-than-expected results in Abbott’s Diabetes Care and Nutrition segments, where sales declined due to market pressures and pricing adjustments. The company cited ongoing challenges in global supply chains and increased competition in key markets. CEO Robert Ford stated during the earnings call that the company remains focused on innovation and cost efficiency but acknowledged near-term headwinds. Abbott’s stock closed at $102.45, down from $110.20 the previous day. The drop extended losses into early trading on January 23, 2026.